Connor Clark & Lunn Investment Management Ltd. Takes $940,000 Position in Evolus, Inc. (NASDAQ:EOLS)

Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 58,046 shares of the company's stock, valued at approximately $940,000. Connor Clark & Lunn Investment Management Ltd. owned about 0.09% of Evolus as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. increased its position in shares of Evolus by 5,627.2% during the second quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company's stock worth $10,276,000 after acquiring an additional 930,566 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Evolus by 24.6% in the second quarter. Bank of New York Mellon Corp now owns 181,093 shares of the company's stock valued at $1,965,000 after acquiring an additional 35,760 shares in the last quarter. Armistice Capital LLC purchased a new position in shares of Evolus during the 2nd quarter worth approximately $3,906,000. California State Teachers Retirement System boosted its position in shares of Evolus by 1.6% during the 1st quarter. California State Teachers Retirement System now owns 48,109 shares of the company's stock worth $674,000 after purchasing an additional 739 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Evolus by 4.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 39,882 shares of the company's stock worth $559,000 after buying an additional 1,637 shares in the last quarter. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Evolus

In other news, CFO Sandra Beaver sold 3,276 shares of the firm's stock in a transaction on Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the transaction, the chief financial officer now directly owns 148,502 shares of the company's stock, valued at approximately $2,224,559.96. This trade represents a 2.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the company's stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $15.85, for a total transaction of $89,251.35. Following the completion of the sale, the chief marketing officer now directly owns 82,375 shares of the company's stock, valued at $1,305,643.75. The trade was a 6.40 % decrease in their position. The disclosure for this sale can be found here. Insiders own 6.10% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on EOLS shares. HC Wainwright reaffirmed a "buy" rating and issued a $27.00 price target on shares of Evolus in a report on Thursday, November 7th. Needham & Company LLC reissued a "buy" rating and issued a $22.00 price objective on shares of Evolus in a research report on Friday, September 13th. Cantor Fitzgerald restated an "overweight" rating on shares of Evolus in a report on Monday, September 16th. Finally, Barclays raised their price target on shares of Evolus from $16.00 to $20.00 and gave the stock an "overweight" rating in a research report on Friday, September 13th.

Evolus Stock Performance

NASDAQ:EOLS traded up $0.97 during midday trading on Thursday, reaching $13.80. 802,620 shares of the company traded hands, compared to its average volume of 595,790. Evolus, Inc. has a twelve month low of $9.32 and a twelve month high of $17.82. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The company has a fifty day moving average price of $15.37 and a 200 day moving average price of $13.86. The firm has a market capitalization of $873.82 million, a price-to-earnings ratio of -15.16 and a beta of 1.31.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.